Rui Liu

PurposeTP53 mutations are among the strongest adverse prognostic factors in large B-cell lymphoma (LBCL) treated with chemoimmunotherapy. Whether this unfavorable prognostic impact persists in the era of chimeric antigen receptor (CAR) T-cell therapy r…

BackgroundSepsis-induced cardiomyopathy (SIC) presents a critical complication in cancer patients, contributing notably to heart failure and elevated mortality rates. While its clinical relevance is well-documented, the intricate molecular mechanisms t…